BPA Call W81XWH22A0005-HT942525F0102

The Defense Health Agency awarded a $169,600 firm fixed-price call under an existing Blanket Purchase Agreement to Biodiscovery LLC, doing business as Daicel Arbor Biosciences, for MYBAITS Mito 384 RXN reagents. This award, issued on February 13, 2025, with an ultimate completion date of February 24, 2025, represents a task order against DHA's $5.3 million single-award BPA with the vendor, which runs through September 27, 2027. The reagents will be delivered to the performance location in Ann Arbor, Michigan, where Biodiscovery manufactures its proprietary molecular biology products. No small business set-aside designation was used for this acquisition, reflecting open competition in the federal marketplace.

Biodiscovery LLC specializes in custom molecular biology and synthetic biology solutions, with a focus on next-generation sequencing, cytogenomics, and cell-free protein expression applications. The MYBAITS reagents being procured support DHA's biomedical research programs and diagnostic development initiatives for military service members. As a foreign-owned, for-profit manufacturer, Biodiscovery has established itself as a key supplier of specialized genomic tools to multiple federal agencies, including the National Human Genome Research Institute, the Centers for Disease Control and Prevention, and the U.S. Department of Agriculture, with individual task orders under the DHA BPA historically ranging from approximately $23,000 to $610,000.